Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an inherited neurodegenerative disorder with symptoms of spastic ataxia, neuropathy, pyramidal sign, finger and foot deformities, and hypermyelination of retinal nerve fibers. SACS is mutated in ARSACS. The clinical diversity of ARSACS is recognized, which sometimes makes its diagnosis difficult. By using homozygosity mapping, we identified a novel homozygous c.12020C > T missense mutation in a consanguineous Japanese family with atypical clinical features. In addition to the absence of spasticity and hypermyelinated retinal nerve fibers, the present case had urinary dysfunction, impotence, and severe constipation, indicating the possibility of autonomic dysfunction. Furthermore, we showed the diagnostic usefulness of MRI even for the case of atypical clinical features. It had been considered that cases without obvious spasticity were very rare, however recent reports on atypical cases as well as our case indicate that ARSACS cases without obvious spasticity might be more frequent than previously thought. We should be aware of atypical features of ARSACS for the correct diagnosis.
Introduction
Autosomal recessive spastic ataxia of CharlevoixSaguenay (ARSACS: MIM 270550) is an inherited neurodegenerative disorder originally found among French Canadians in the Charlevoix-Saguenay-Lac-Saint-Jean region of Quebec, Canada. The clinical features are early-onset spastic ataxia, nystagmus, axonal and demyelinating neuropathy, pyramidal tract signs, finger and foot deformities, and hypermyelination of retinal nerve fiber. On autopsy, atrophy of the upper vermis and the loss of Purkinje cells in the cerebellum are found. It had been recognized as a highly uniform disease in Quebec (1) . In 2000, the gene responsible for ARSACS (SACS) was identified (2) . SACS gene was originally thought to consist of a single giant exon, but eight new coding exons upstream of the gigantic exon were later found (3) . Only two causal mutations were found among Quebec patients and a founder effect caused by the settlement patterns from the late 17th to mid-19th century is considered in ARSACS (2, 4) . Afterwards, cases with SACS mutations were also reported outside Quebec. Now ARSACS is known to exist worldwide (5) . Recent reports have also revealed the clinical diversity of ARSACS (6, 7) which sometimes makes its diagnosis difficult.
By homozygosity mapping, we identified a novel homozygous missense mutation in SACS in a Japanese family with an atypical clinical phenotype and characteristic MRI findings.
mode of inheritance was suspected because of the consanguinity. Blood serum test, physiological test such as electrocardiogram, bladder scan to evaluate the postvoid residual urine volume, electrophysiological study including nerve conduction study and somatosensory evoked potential, funduscopic examination of the retina, and MRI study of the brain and spine were performed in addition to the neurological examination.
Genetic study
Blood sample from the proband and the saliva samples from siblings were obtained with informed consent. Genomic DNA was obtained from peripheral blood leukocytes using QuickGene 610-L (FUJIFILM, Tokyo, Japan) and from saliva using Oragene ·DNA (DNA Genotek Inc., Ottawa, Ontario, Canada).
We performed the genome-wide linkage analysis of the consanguineous family with a proband and three unaffected siblings using Affymetrix Human Mapping single nucleotide polymorphism 10K XbaI 142 2.0 array (Affymetrix, Santa Clara, CA, USA). SNP genotyping were undertaken according to the manufacture's protocol. Single nucleotide polymorphism (SNP) allele calls were generated by the GeneChip Genotyping analysis Software (Gtypev4. Each of the coding exons and intron-exon border of SACS, which was the only known causative gene within the candidate loci, was amplified by PCR using specific primers kindly offered from Dr. Shimazaki (Jichi Medical University School of Medicine) and Dr. Takiyama (University of Yamanashi). PCR products were purified with ExoSAP (USB, Cleveland, OH, USA) and sequenced with BigDye Terminator chemistry version 3 according to the standard protocol (Applied Biosystems, Foster City, CA, USA). The reaction mixture was purified using Sephadex G-50 (GE Healthcare, Buckinghamshire, UK) and multiscreen-96 (Millipore, Billerica, MA, USA). Sequences were obtained on the ABI Genetic Analyzer 3100 (Applied Biosystems) and analyzed with sequence analysis software version 5.1.1 (Applied Biosystems) and Sequencher 4.8-build 3767 (GeneCodes Corporation, Ann Arbor, MI, USA). Experimental protocols were approved by the Committee for Ethical Issue at Yokohama City University School of Medicine.
Case Report
The patient was born under the first-cousin marriage. He started to walk after two years of age. Walking unsteadiness was obvious in his first decade, and was slowly progressive. He needed assistance when walking up stairs in his twenties. He fell frequently because of his unsteady and steppage gait. He was diagnosed as spinocerebellar degeneration when he was 38 years old. He became wheelchair bound at 44 years of age. At that time dysarthria and dysphagia were also observed. He visited our hospital when was 45 years old. On neurological examination at age 54, he had slurred and explosive speech, saccadic eye movement with poor ocular pursuit, dysphagia, cerebellar ataxia in all extremities. Babinski sign was positive. The deep tendon reflexes were diminished or disappeared except for patellar tendon reflex, which was normal. Muscle atrophy and weakness of lower extremities without spasticity was obvious. Position and vibration sense were also decreased in the lower extremities. Interestingly he had urination disorder including pollakiuria, decreased urinary stream, and infrequent urinary incontinence without awareness. He also had impotence, and severe constipation necessitating hospitalization one time. Pes cavus and hammertoe deformity were noticed. He had normal intellectual ability. Hypermyelination of retinal nerve fiber was not observed by funduscopy. Blood sugar, serum betalipoproteins, HDL lipoproteins, vitamin E were within normal range. On electrocardiogram (ECG), CVR-R was normal. The residual urine volume measured with bladder scan just after urination was 83 mL, possibly suggesting urination disorder. It increased to 136 mL a few years later. On nerve conduction study, severe axonal sensori-motor neuropathy with mild demyelinating features was revealed. On SEP study, N20 component of median nerve SEP was delayed, and P38 component of tibial nerve SEP was not evoked (Table 1). MRI findings revealed cerebellar atrophy, especially in the upper vermis, linear pontine hypointensities on T2-weighted imaging, and cervicothoracic spinal atrophy (Figure B) .
Molecular findings
We performed homozygosity mapping and identified 10 informative homozygous regions which were larger than 3-Mb in length ( Table 2) . One of those candidate locus was a 10.3-Mb homozygous region at chromosome 13q11-q12.2 with the maximum LOD score 1.55. Within this region, SACS was the only known causative gene for spinocerebellar ataxia. By direct sequencing, novel homozygous c.12020C > T (p.Ser4007Phe) was identified in the patient's sample. Heterozygous c.12020C > T mutation was observed in one of the unaffected siblings, and no mutation in other two unaffected siblings, which was compatible with the haplotype pattern expected from the SNP genotyping, being consistent with the affected status as an autosomal recessive model ( Figure A) . The amino residue, Ser4007 was evolutionally conserved from anolis to human ( Figure C) . Four out of 5 computational prediction algorithms (8) (9) (10) (11) predicted this mutation to be pathogenic (Table 3 ). This mutation was not observed in 186 normal Japanese chromosomes.
Discussion
We reported an atypical Japanese case of ARSACS with a novel homozygous missense mutation of the SACS gene. Notably, spasticity and hypermyelination of retinal nerve fibers which are characteristic features of ARSACS were not observed in this case. Spasticity is one of the major symptoms of ARSACS inside and outside Quebec. It usually becomes worse as the disease progresses and is prevalent in older patients (1). The cases without obvious spasticity have been considered to be very rare judging from the reviews (6). The cases showing no spasticity were rarely observed, especially in Japanese (12, 13) . Recently some additional cases without spasticity have been reported as atypical cases from other ethnic backgrounds, as well as Japanese (14, 15) . We should be aware of atypical features in ARSACS for the correct diagnosis. Although spasticity was not obvious in the present patient, ARSACS should not be excluded. The presence of Babinski's sign in spite of distal muscle weakness evident with a history of steppage gait is a strong reminder of pyramidal tract involvement. While the hypermyelination of retinal nerve fibers is a specific finding of ARSACS, this finding is not always observed in patients outside Quebec (16) . Another atypical clinical symptom of the present case was urinary dysfunction, impotence, and severe constipation. These symptoms might be due to the pyramidal tract dysfunction, but the progression of urinary dysfunction might indicate the possibility of mild autonomic dysfunction. Urinary urgency/incontinency is occasionally recorded as a symptom of ARSACS. Masciullo et al. have reported an ARSACS case with urinary retention and severe constipation manifesting the intestinal pseudo-obstruction (17) . They speculated that the loss of the sacsin protein function leads to the dysfunction of the autonomic ganglia neurons. However their case also had type 1 diabetes which might cause the autonomic dysfunction. Further studies on autonomic function of ARSACS cases will be necessary.
Although the present case had atypical clinical symptoms, MRI findings of this case were quite typical. Early atrophy of superior vermis, and linear hypointensity on T2-and fluid-attenuated inversion recovery (FLAIR)-weighted images of the pons are characteristic of ARSACS (18) . We showed here that these MRI findings could indeed help to SACS encodes the Sacsin protein, a 520 kDa protein expressed highly in neurons, particularly within brain motor system, and cerebellar Purkinje cells (19) . Sacsin contains several domains shown in Figure C (20) . The c.12020C > T (p.Ser4007Phe) mutation is located upstream of DNA-J domain coding region. Although mutations reported to date spread over entire coding exons or exon-intron border without mutation hotspot, all mutations were detected upstream the DNA-J domain, which was implicated in the chaperonemediated folding process. Thus it is speculated that ARSACS phenotype might be related to the loss of chaperone function of Sacsin proteinb (16) . Further investigation on the function of Sacsin protein is necessary.
It is still obscure whether there is any genotypephenotype correlation on ARSACS. Takiyama summarized the clinical features of Quebec patients and non-Quebec patients from Japan, Italy, Spain, Tunisia, and Turkey (7) . In contrast to the Quebec patients who were clinically uniform with core ARSACS symptoms, non-Quebec patients showed clinical diversities even in its core symptoms. Even most frequent symptoms were different among patients from each country. Ethnic background might modify the ARSACS phenotype, making it complicated to make a correct diagnosis.
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